uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
P/E ratio for uniQure N.V. (QURE)
P/E ratio as of 2023: -1.05
According to uniQure N.V.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.05. At the end of 2022 the company had a P/E ratio of -8.36.
P/E ratio history for uniQure N.V. from 2010 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.05 |
| 2022 | -8.36 |
| 2021 | 2.89 |
| 2020 | -12.85 |
| 2019 | -22.39 |
| 2018 | -12.33 |
| 2017 | -6.58 |
| 2016 | -1.91 |
| 2015 | -4.67 |
| 2014 | -5.63 |
| 2013 | -6.94 |
| 2012 | -13.21 |
| 2011 | -11.46 |
| 2010 | 0.00 |